Tags

Type your tag names separated by a space and hit enter

Resection of portal and/or superior mesenteric vein and reconstruction by using allogeneic vein for pT3 pancreatic cancer.
J Gastroenterol Hepatol. 2016 Aug; 31(8):1498-503.JG

Abstract

BACKGROUND AND AIM

There is still controversy on the outcomes of portal vein (PV) and/or superior mesenteric vein (SMV) resection in pancreatic cancer, and there are few reports about pancreaticoduodenectomy (PD) with PV/SMV resection and reconstruction by using allogeneic vein. This study is to explore the outcomes of PD with PV/SMV resection and reconstruction by using allogeneic vein for pT3 pancreatic cancer with venous invasion.

METHODS

Clinicopathological data of patients underwent PD with en bloc resection of PV/SMV and reconstruction by using internal iliac from August 20, 2013 to July 25, 2015 were collected and the data of patients with pT3 stage pancreatic head cancer with PV/SMV invasion were analyzed. The short- and long-term outcomes were presented.

RESULTS

Thirty patients met the criteria of this study. PV resection and reconstruction were performed for 12 patients, SMV for 9 patients, and PV + SMV for 9 patients, respectively. The median operation time was 460 min, and the median intraoperative blood loss was 450 mL. R0 resection rate was 93.3%, total incidence of complications was 23.3%, and incidence of pancreatic fistula was 10%. The 1-year and 2-year overall survival rates were 68.6% and 39.2%, 1-year and 2-year disease free survival rates were 44.8% and 17.1%.

CONCLUSIONS

PD with en bloc resection of PV/SMV and reconstruction by using allogeneic vein was safe and feasible for patients with pT3 stage pancreatic head cancer with PV/SMV invasion. A large-scale research with longer follow-up time is required to draw a significant conclusion.

Authors+Show Affiliations

Department of Hepatobiliary Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.Department of Hepatobiliary Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.Department of Hepatobiliary Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.Department of Hepatobiliary Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.Department of Hepatobiliary Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.Department of Hepatobiliary Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.Department of Hepatobiliary Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

26825612

Citation

Zhang, Xing-Mao, et al. "Resection of Portal And/or Superior Mesenteric Vein and Reconstruction By Using Allogeneic Vein for pT3 Pancreatic Cancer." Journal of Gastroenterology and Hepatology, vol. 31, no. 8, 2016, pp. 1498-503.
Zhang XM, Fan H, Kou JT, et al. Resection of portal and/or superior mesenteric vein and reconstruction by using allogeneic vein for pT3 pancreatic cancer. J Gastroenterol Hepatol. 2016;31(8):1498-503.
Zhang, X. M., Fan, H., Kou, J. T., Zhang, X. X., Li, P., Dai, Y., & He, Q. (2016). Resection of portal and/or superior mesenteric vein and reconstruction by using allogeneic vein for pT3 pancreatic cancer. Journal of Gastroenterology and Hepatology, 31(8), 1498-503. https://doi.org/10.1111/jgh.13299
Zhang XM, et al. Resection of Portal And/or Superior Mesenteric Vein and Reconstruction By Using Allogeneic Vein for pT3 Pancreatic Cancer. J Gastroenterol Hepatol. 2016;31(8):1498-503. PubMed PMID: 26825612.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Resection of portal and/or superior mesenteric vein and reconstruction by using allogeneic vein for pT3 pancreatic cancer. AU - Zhang,Xing-Mao, AU - Fan,Hua, AU - Kou,Jian-Tao, AU - Zhang,Xin-Xue, AU - Li,Ping, AU - Dai,Yang, AU - He,Qiang, PY - 2015/12/16/received PY - 2016/01/20/revised PY - 2016/01/22/accepted PY - 2016/1/31/entrez PY - 2016/1/31/pubmed PY - 2017/5/16/medline KW - allogeneic vein KW - outcomes KW - pancreatic cancer KW - pancreaticoduodenectomy KW - reconstruction SP - 1498 EP - 503 JF - Journal of gastroenterology and hepatology JO - J. Gastroenterol. Hepatol. VL - 31 IS - 8 N2 - BACKGROUND AND AIM: There is still controversy on the outcomes of portal vein (PV) and/or superior mesenteric vein (SMV) resection in pancreatic cancer, and there are few reports about pancreaticoduodenectomy (PD) with PV/SMV resection and reconstruction by using allogeneic vein. This study is to explore the outcomes of PD with PV/SMV resection and reconstruction by using allogeneic vein for pT3 pancreatic cancer with venous invasion. METHODS: Clinicopathological data of patients underwent PD with en bloc resection of PV/SMV and reconstruction by using internal iliac from August 20, 2013 to July 25, 2015 were collected and the data of patients with pT3 stage pancreatic head cancer with PV/SMV invasion were analyzed. The short- and long-term outcomes were presented. RESULTS: Thirty patients met the criteria of this study. PV resection and reconstruction were performed for 12 patients, SMV for 9 patients, and PV + SMV for 9 patients, respectively. The median operation time was 460 min, and the median intraoperative blood loss was 450 mL. R0 resection rate was 93.3%, total incidence of complications was 23.3%, and incidence of pancreatic fistula was 10%. The 1-year and 2-year overall survival rates were 68.6% and 39.2%, 1-year and 2-year disease free survival rates were 44.8% and 17.1%. CONCLUSIONS: PD with en bloc resection of PV/SMV and reconstruction by using allogeneic vein was safe and feasible for patients with pT3 stage pancreatic head cancer with PV/SMV invasion. A large-scale research with longer follow-up time is required to draw a significant conclusion. SN - 1440-1746 UR - https://www.unboundmedicine.com/medline/citation/26825612/Resection_of_portal_and/or_superior_mesenteric_vein_and_reconstruction_by_using_allogeneic_vein_for_pT3_pancreatic_cancer_ L2 - https://doi.org/10.1111/jgh.13299 DB - PRIME DP - Unbound Medicine ER -